1-1 of 1
Zusheng Xu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5332.
https://doi.org/10.1182/blood-2018-99-110585
Published: 2018